Navigation Links
Bionovo Announces Third Quarter 2011 Highlights and Financial Results
Date:11/10/2011

tency compared to the highest dose tested in our Phase 2 study. This level of efficacy at 4 weeks is equivalent to or superior to estrogen-based hormone therapy.
  • The Company successfully completed non-clinical toxicology studies of Menerba in two animal species.  As expected, no serious adverse events or toxicities were observed to date from these studies, at doses much higher than are being tested in the Phase 3 clinical trial. The drug was well tolerated by the animals.
  • The Company has completed the manufacture of the requisite ten batches for the Phase 3 clinical trial of Menerba, and demonstrated to the FDA excellent consistency and quality.

  • Third Quarter ResultsTotal operating expenses for the three months ending September 30, 2011 were $6.4 million compared to $4.7 million for the same period in 2010. Total operating expenses for the third quarter included manufacturing costs at the Company's cGMP manufacturing facility in Hayward, California for ten clinical batches of Menerba, clinical trial costs for the tolerability trial assessing the safety and tolerability of higher doses of Menerba and other costs in preparation for the Company's Phase 3 trial of Menerba.

    The Company reported a net loss for the three months ended September 30, 2011 of $3.9 million, or $0.07 per share, compared with a net loss of $4.6 million, or $0.21 per share, for the same period in 2010.  The difference in net loss is primarily due to the increase in operating expenses as described above offset by the change in fair value of the Company's warrant liability representing a gain of $2.3 million included in non-operating income for the three months ended September 30, 2011.

    The Company ended the quarter with $8.1 million in cash, cash equivalents and short term investments, and began the quarter with $13.0 million, a difference of $4.9 million. The cash balance at the end of the quarter reflects the proceeds of the Company'
    '/>"/>

    SOURCE Bionovo, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related medicine technology :

    1. Bionovo Initiates Menerba (MF101) Phase 3 Clinical Trial for Menopausal Hot Flashes
    2. Bionovo to Present Tissue Selective Estrogen Receptor Modulators for Obesity at the 22nd Annual Meeting of the North American Menopause Society
    3. Bionovo Announces an Additional 180 Day Period to Regain Compliance With Nasdaqs Bid Price Rule
    4. CORRECTED: Bionovo Announces Second Quarter 2011 Highlights and Financial Results
    5. Bionovo Announces Second Quarter 2011 Highlights and Financial Results
    6. Bionovo to Present the Clinical Promise of Menerba (MF101) for Postmenopausal Vasomotor Symptoms at World Congress on Menopause
    7. Bionovo to Announce First Quarter Financial Results on Wednesday, May 11, 2011
    8. Bionovo Announces Enrollment Started in the Menerba (MF101) Phase 1 "Tolerability" Clinical Trial for Menopausal Hot Flushes
    9. Bionovo Announces 2010 Highlights and Year-End Financial Results
    10. Bionovo, Inc. to Announce Fourth Quarter Fiscal Year 2010 Financial Results on Tuesday, March 15, 2011
    11. Bionovo to Present at the Cowen and Company 31st Annual Healthcare Conference
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:10/17/2014)... , Oct. 17, 2014 Research ... "Research and Development Prospect of China Dialysis ... Based on the 2013 version, this ... policies about dialysis industry and the relevant effect ... about dialysis industry segmentations. Moreover, it analyzes Chinese ...
    (Date:10/17/2014)... , Oct. 17, 2014 The ... Medical Technology Policy: The Green Park ... FDA, public and private payers, medical device and ... and other experts January 12, 2015 at its ... value of weight loss treatments.  Participants will discuss ...
    (Date:10/17/2014)... -- China Biologic Products, Inc. (NASDAQ: CBPO, "China Biologic" ... biopharmaceutical company in China , ... from the China Food and Drug Administration (the ... concentrate ("PCC") at its Shandong Taibang facility. The ... facility for Good Manufacturing Practices ("GMP") compliance in ...
    Breaking Medicine Technology:Research and Development Prospect of China Dialysis Market, 2014-2018 2Research and Development Prospect of China Dialysis Market, 2014-2018 3Green Park Collaborative to Discuss Comparative Effectiveness and Value of Weight Loss Treatments 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 2China Biologic Receives Approval for Commercial Manufacturing of Human Prothrombin Complex Concentrate at Shandong Taibang Facility 3
    ... Network, Inc. (Other OTC: CNWI.PK) (the "Company") today announced that ... "Reverse Stock Split"). The Reverse Stock Split will take effect ... 2011 (the "Effective Date"). On the Effective Date, the Company,s ... approximately 20 business days, after which it will revert to ...
    ... SAN FRANCISCO, Calif., May 5, 2011 Rigel Pharmaceuticals, Inc. ... the company,s chief financial officer, is scheduled to present a ... Care Conference in Las Vegas on Tuesday, May 10th at ... The presentation will be webcast live and can ...
    Cached Medicine Technology:Cardiac Network Announces Reverse Stock Split 2
    (Date:10/20/2014)... Unveiled at the Sept. 18 board meeting, The Center ... hospital ROI on membership dues at 12.5. In other words, ... in value to member hospitals. The calculation used to determine ... , “This is the first time we’ve actually been ... methodology is really sound,” said Bill Ryan , president ...
    (Date:10/20/2014)... Houston, Texas (PRWEB) October 20, 2014 ... invited to present the key elements of his innovative ... visiting professor to plastic surgery residents and faculty at ... (UTMB) , where he, too, was once a medical ... of the largest private cosmetic plastic surgery practices in ...
    (Date:10/19/2014)... (PRWEB) October 20, 2014 The ... iPage ( http://www.top10bestseohosting.com/go/iPage/ ) and GreenGeeks are the ... excellent platforms for those who want to buy ... same time. , The IT manager of Top10BestSEOHosting.com ... the most recommended suppliers for everyone. A lot ...
    (Date:10/19/2014)... Texas (PRWEB) October 20, 2014 ... development for Partial Seizure, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ... Partial Seizure and special features on late-stage and ...
    (Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides many ... latest designs of 2014 mother of the bride ... are offered with big discounts, up to 70% off. ... can enjoy this special offer. , Owing to ... become one of the leading brands in the global ...
    Breaking Medicine News(10 mins):Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 2Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 3Health News:Scorecard Estimates Hospital ROI at $12.50 for every $1 Spent on Dues 4Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Top10BestSEOHosting.com Considers iPage And GreenGeeks As The Best Dedicated Server Hosting Suppliers 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2
    ... site in a mouse brain well connected to other ... entire brainafter one injection of gene therapy. If these ... may have a potential method for gene therapy to ... neurological disorders, such as Tay-Sachs disease. , Researchers from ...
    ... to Health Coverage Expected to Increase for Small Business Owners ... http://www.bluecrossca.com/click4biz ... business sector,is one of the fastest growing segments of California,s ... provide their,employees with health insurance. Blue Cross of California has ...
    ... in antioxidant vitamins and minerals does not seem to prevent ... finds a study published on bmj.com today. , ... loss in older people. It is caused by the progressive ... in the centre of the retina at the back of ...
    ... MONICA, Calif., Oct. 8 Proposed,regulations that would ... stem cell research grants to for-profit organizations fail,to ... for California taxpayers,paying for the research, the Foundation ... "To ensure that the people who have paid ...
    ... fitness,and healthy living in communities across the USA, is ... held in conjunction with the 30th,anniversary of the Detroit ... Expo, which runs Oct. 19-20 at Cobo,Center, exemplifies that ... that provide services to runners. The Detroit Free ...
    ... Veterinary Medical Association awarded its 2007 Student/Recent,Graduate Award, ... in Lacey. (Logo: http://www.newscom.com/cgi-bin/prnh/20070613/WSVMALOGO ), ... of his dedication to,organized veterinary medicine in Washington. ... Veterinary Medicine, he has served as a,member of ...
    Cached Medicine News:Health News:One shot of gene therapy spreads through brain in animal study 2Health News:One shot of gene therapy spreads through brain in animal study 3Health News:New Online Tool Makes Enrollment in Blue Cross of California Easier 2Health News:Antioxidants do not prevent degenerative eye disease 2Health News:Revised California Stem Cell Research Rules Fail to Ensure Affordable Access to Cures, Consumers Warn 2Health News:Saturn Shows Its Commitment to Health and Fitness by Becoming Expo Title Sponsor for The Detroit Free Press/Flagstar Marathon 2Health News:Lacey Veterinarian Awarded 2007 WSVMA Recent Graduate Award 2
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
    ... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
    ... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
    Medicine Products: